
    
      This study is a single-dose, randomized, double-blind, placebo-controlled, 2-treatment,
      2-sequence, 2-way crossover, multicenter study in patients with a documented history of EIB,
      with or without underlying asthma. Each patient will participate in the study for
      approximately 5 weeks. Each patient will complete 2 screening visits (SV1 and SV2), 2
      treatment visits (TV1 and TV2), and a follow-up telephone call (FV).
    
  